Key Dates

Related Announcements

• October 31, 2024 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional). See NOFO PAR-25-143. 

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform potential applicants of NINDS's scientific objectives, resources communicating scientific interests for Dissemination and Implementation Research in Health (R21 Clinical Trial Optional), PAR-25-143. Applicants are encouraged to contact the Scientific/Research contact to ensure that the aims of the proposed project are consistent with the NINDS mission.

Section I. Notice of Funding Opportunity Description - Information relevant to Specific Institutes/Centers

Additional language for NINDS:

National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke (NINDS) is interested in mission relevant applications. The NINDS supports dissemination and implementation research focused on identifying, monitoring, scaling-up, and/or testing strategies for overcoming environmental, social, community, structural, and healthcare system factors that lead to or are associated with disparities (or inequities) in neurological diseases and care across the lifespan. Some priority disease areas include stroke and other cerebrovascular diseases, Alzheimer’s disease-related dementias (including frontotemporal neurodegeneration, Lewy body dementias, vascular contributions to cognitive impairment and dementia and mixed etiology dementia), epilepsy, migraine, nervous system infections, spinal cord injury, headache, Parkinson's disease, and other neurodegenerative disorders, brain trauma, neurodevelopmental disorders, and the neurological consequences of HIV/AIDS. Applicants are encouraged to incorporate community engagement strategies into their study designs. Applicants are also encouraged to incorporate a plan to enhance diverse perspectives (https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp) and community engagement strategies into their study designs when appropriate.

Applicants considering submitting a clinical trial should review the NINDS Clinical Trial policy (https://www.ninds.nih.gov/current-research/research-funded-ninds/clinical-research).

Clinical trials are research studies in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. For this funding announcement, only the following types of clinical trials will be supported:

• Mechanistic trials, defined as studies designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention (i.e., HOW an intervention works, but not IF it works or is safe).
• Basic Experimental Studies with Humans (BESH), defined as basic research studies involving humans that seek to understand the fundamental aspects of phenomena and of observable facts without specific applications towards processes or products in mind.

No other changes to this NOFO.

Inquiries

Please direct all inquiries to:

Richard T Benson, Ph.D.
NINDS - NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Phone: 301-496-9135
E-mail: richard.benson@nih.gov